Academy Home  / Resources  / Report & Therapy Quick Reference

ABV Report & Therapy Quick Reference

Explore the 'ABV Microbiome Report & Therapy Quick Reference,' a comprehensive cheat sheet by Dr. Tonya Cooksey designed to aid in interpreting Gut Microbiome Health Test Reports.

Browse Supporting Research

Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention
and therapy of gastrointestinal disorders

Kelesidis et al (2012). Therapeutic Advances in Gastroenterology.

Several clinical trials and experimental studies strongly suggest a place for Saccharomyces boulardii as a biotherapeutic agent for the prevention and treatment of several gastrointestinal diseases. S. boulardii mediates responses resembling the protective effects of the normal healthy gut flora. The multiple mechanisms of action of S. boulardii and its properties may explain its efficacy and beneficial effects in acute and chronic gastrointestinal diseases that have been confirmed by clinical trials.

Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT

Suez et al (2018). Cell.

This study compared the effects of probiotics versus autologous fecal microbiome transplantation (aFMT) on gut microbiome recovery after antibiotic use in mice and humans. Probiotics delayed gut microbiome and gene expression recovery, while aFMT resulted in a rapid and near-complete recovery. These findings suggest that probiotics may hinder post-antibiotic gut recovery, highlighting the need for alternative approaches like aFMT or personalized probiotics.

PHAGE Study: Effects of Supplemental Bacteriophage Intake on Inflammation and Gut Microbiota in Healthy Adults

Febvre et al (2019). Nutrients.

This study investigated the impact of consuming a commercial E. coli-targeting bacteriophage cocktail on the gut microbiome of healthy adults. In a placebo-controlled trial, participants consumed phages for 28 days. While phage consumption reduced E. coli levels, it did not significantly disrupt overall gut microbiome diversity. However, specific bacterial populations shifted, including increases in beneficial butyrate-producing bacteria. Inflammatory markers and lipid metabolism remained largely unchanged, except for a small decrease in interleukin-4. These findings suggest that bacteriophages can selectively target specific gut bacteria without broadly disrupting the microbial community.

Ready to integrate microbiome medicine into your practice?

FMT Gut Restore Products

S. boulardii + FOS Powder

GI Relief Supplements

Go to top